Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin

A synergistic combination nanotherapy for ovarian cancer treatment

Liqiong Cai, Gaofei Xu, Changying Shi, Dandan Guo, Xu Wang, Juntao Luo

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Cisplatin (CDDP) and paclitaxel (PTX) are two established chemotherapeutic drugs used in combination for the treatment of many cancers, including ovarian cancer. We have recently developed a three-layered linear-dendritic telodendrimer micelles (TM) by introducing carboxylic acid groups in the adjacent layer via "thio-ene" click chemistry for CDDP complexation and conjugating cholic acids via peptide chemistry in the interior layer of telodendrimer for PTX encapsulation. We hypothesize that the co-delivery of low dosage PTX with CDDP could act synergistically to increase the treatment efficacy and reduce their toxic side effects. This design allowed us to co-deliver PTX and CDDP at various drug ratios to ovarian cancer cells. The invitro cellular assays revealed strongest synergism in anti-tumor effects when delivered at a 1:2 PTX/CDDP loading ratio. Using the SKOV-3 ovarian cancer xenograft mouse model, we demonstrate that our co-encapsulation approach resulted in an efficient tumor-targeted drug delivery, decreased cytotoxic effects and stronger anti-tumor effect, when compared with free drug combination or the single loading TM formulations.

Original languageEnglish (US)
Pages (from-to)456-468
Number of pages13
JournalBiomaterials
Volume37
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Oncology
Paclitaxel
Ovarian Neoplasms
Cisplatin
Tumors
Encapsulation
Micelles
Neoplasms
Cholic Acids
Click Chemistry
Pharmaceutical Preparations
Complexation
Carboxylic acids
Peptides
Poisons
Assays
Drug Combinations
Carboxylic Acids
Cells
Heterografts

Keywords

  • Cisplatin
  • Combination chemotherapy
  • Drug delivery
  • Ovarian cancer
  • Paclitaxel
  • Synergism

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin : A synergistic combination nanotherapy for ovarian cancer treatment. / Cai, Liqiong; Xu, Gaofei; Shi, Changying; Guo, Dandan; Wang, Xu; Luo, Juntao.

In: Biomaterials, Vol. 37, 01.01.2015, p. 456-468.

Research output: Contribution to journalArticle

Cai, Liqiong ; Xu, Gaofei ; Shi, Changying ; Guo, Dandan ; Wang, Xu ; Luo, Juntao. / Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin : A synergistic combination nanotherapy for ovarian cancer treatment. In: Biomaterials. 2015 ; Vol. 37. pp. 456-468.
@article{d2b0f30797a14707ad6b1ff17480ae81,
title = "Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: A synergistic combination nanotherapy for ovarian cancer treatment",
abstract = "Cisplatin (CDDP) and paclitaxel (PTX) are two established chemotherapeutic drugs used in combination for the treatment of many cancers, including ovarian cancer. We have recently developed a three-layered linear-dendritic telodendrimer micelles (TM) by introducing carboxylic acid groups in the adjacent layer via {"}thio-ene{"} click chemistry for CDDP complexation and conjugating cholic acids via peptide chemistry in the interior layer of telodendrimer for PTX encapsulation. We hypothesize that the co-delivery of low dosage PTX with CDDP could act synergistically to increase the treatment efficacy and reduce their toxic side effects. This design allowed us to co-deliver PTX and CDDP at various drug ratios to ovarian cancer cells. The invitro cellular assays revealed strongest synergism in anti-tumor effects when delivered at a 1:2 PTX/CDDP loading ratio. Using the SKOV-3 ovarian cancer xenograft mouse model, we demonstrate that our co-encapsulation approach resulted in an efficient tumor-targeted drug delivery, decreased cytotoxic effects and stronger anti-tumor effect, when compared with free drug combination or the single loading TM formulations.",
keywords = "Cisplatin, Combination chemotherapy, Drug delivery, Ovarian cancer, Paclitaxel, Synergism",
author = "Liqiong Cai and Gaofei Xu and Changying Shi and Dandan Guo and Xu Wang and Juntao Luo",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.biomaterials.2014.10.044",
language = "English (US)",
volume = "37",
pages = "456--468",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin

T2 - A synergistic combination nanotherapy for ovarian cancer treatment

AU - Cai, Liqiong

AU - Xu, Gaofei

AU - Shi, Changying

AU - Guo, Dandan

AU - Wang, Xu

AU - Luo, Juntao

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cisplatin (CDDP) and paclitaxel (PTX) are two established chemotherapeutic drugs used in combination for the treatment of many cancers, including ovarian cancer. We have recently developed a three-layered linear-dendritic telodendrimer micelles (TM) by introducing carboxylic acid groups in the adjacent layer via "thio-ene" click chemistry for CDDP complexation and conjugating cholic acids via peptide chemistry in the interior layer of telodendrimer for PTX encapsulation. We hypothesize that the co-delivery of low dosage PTX with CDDP could act synergistically to increase the treatment efficacy and reduce their toxic side effects. This design allowed us to co-deliver PTX and CDDP at various drug ratios to ovarian cancer cells. The invitro cellular assays revealed strongest synergism in anti-tumor effects when delivered at a 1:2 PTX/CDDP loading ratio. Using the SKOV-3 ovarian cancer xenograft mouse model, we demonstrate that our co-encapsulation approach resulted in an efficient tumor-targeted drug delivery, decreased cytotoxic effects and stronger anti-tumor effect, when compared with free drug combination or the single loading TM formulations.

AB - Cisplatin (CDDP) and paclitaxel (PTX) are two established chemotherapeutic drugs used in combination for the treatment of many cancers, including ovarian cancer. We have recently developed a three-layered linear-dendritic telodendrimer micelles (TM) by introducing carboxylic acid groups in the adjacent layer via "thio-ene" click chemistry for CDDP complexation and conjugating cholic acids via peptide chemistry in the interior layer of telodendrimer for PTX encapsulation. We hypothesize that the co-delivery of low dosage PTX with CDDP could act synergistically to increase the treatment efficacy and reduce their toxic side effects. This design allowed us to co-deliver PTX and CDDP at various drug ratios to ovarian cancer cells. The invitro cellular assays revealed strongest synergism in anti-tumor effects when delivered at a 1:2 PTX/CDDP loading ratio. Using the SKOV-3 ovarian cancer xenograft mouse model, we demonstrate that our co-encapsulation approach resulted in an efficient tumor-targeted drug delivery, decreased cytotoxic effects and stronger anti-tumor effect, when compared with free drug combination or the single loading TM formulations.

KW - Cisplatin

KW - Combination chemotherapy

KW - Drug delivery

KW - Ovarian cancer

KW - Paclitaxel

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=84922250825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922250825&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2014.10.044

DO - 10.1016/j.biomaterials.2014.10.044

M3 - Article

VL - 37

SP - 456

EP - 468

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -